Sangamo Therapeutics, Inc.
SGMO
$0.44
$0.013.48%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 581.00K | 18.31M | 6.44M | 7.55M | 49.41M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 581.00K | 18.31M | 6.44M | 7.55M | 49.41M |
| Cost of Revenue | 28.14M | 27.08M | 24.81M | 23.68M | 27.73M |
| Gross Profit | -27.56M | -8.78M | -18.37M | -16.12M | 21.68M |
| SG&A Expenses | 7.99M | 9.08M | 10.06M | 9.77M | 8.85M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 36.13M | 36.16M | 34.87M | 33.44M | 36.58M |
| Operating Income | -35.55M | -17.86M | -28.43M | -25.89M | 12.83M |
| Income Before Tax | -35.09M | -19.96M | -30.48M | -23.82M | 10.76M |
| Income Tax Expenses | -161.00K | 27.00K | 119.00K | -427.00K | 88.00K |
| Earnings from Continuing Operations | -34.93M | -19.99M | -30.60M | -23.40M | 10.67M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -34.93M | -19.99M | -30.60M | -23.40M | 10.67M |
| EBIT | -35.55M | -17.86M | -28.43M | -25.89M | 12.83M |
| EBITDA | -34.56M | -16.86M | -27.41M | -24.65M | 14.05M |
| EPS Basic | -0.11 | -0.08 | -0.14 | -0.11 | 0.05 |
| Normalized Basic EPS | -0.07 | -0.05 | -0.08 | -0.07 | 0.04 |
| EPS Diluted | -0.11 | -0.08 | -0.14 | -0.12 | 0.04 |
| Normalized Diluted EPS | -0.07 | -0.05 | -0.08 | -0.07 | 0.04 |
| Average Basic Shares Outstanding | 304.27M | 256.95M | 220.27M | 210.19M | 208.35M |
| Average Diluted Shares Outstanding | 304.27M | 256.95M | 220.27M | 210.19M | 214.33M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |